Quick Answer
Bluejay Diagnostics, Inc. reported Net Income Loss of -$6.85 million for the year ending 2025.
- Bluejay Diagnostics, Inc. showed an increase of +11.3% in Net Income Loss from 2024 to 2025.
- This data is from Bluejay Diagnostics, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: -$128.0 thousand | Q1 2021: -$194.2 thousand | Q2 2021: $640.2 thousand | Q3 2021: -$1.19 million | Q1 2022: -$2.01 million | Q2 2022: -$1.94 million | Q3 2022: -$2.96 million | Q1 2023: -$2.54 million | Q2 2023: -$2.81 million | Q3 2023: -$2.30 million | Q1 2024: -$2.33 million | Q2 2024: -$2.48 million | Q3 2024: -$1.48 million | Q1 2025: -$1.86 million | Q2 2025: -$1.96 million | Q3 2025: -$1.60 million.
- Over the full 6 years of available data (2020 to 2025), Bluejay Diagnostics, Inc.'s Net Income Loss has declined by 491.3%.
- Historical annual values: Fiscal year 2025: -$6.85 million | Fiscal year 2024: -$7.72 million | Fiscal year 2023: -$9.95 million | Fiscal year 2022: -$9.30 million | Fiscal year 2021: -$3.49 million | Fiscal year 2020: -$1.16 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: